166 related articles for article (PubMed ID: 12800838)
1. [Off-label use in psychopharmacotherapy. Letter to Federal Minister Ulla Schmidt, Pulheim, 22 January 2003].
Fritze J
Nervenarzt; 2003 Apr; 74(4):389; discussion 390. PubMed ID: 12800838
[No Abstract] [Full Text] [Related]
2. [Open letter to minister of health. Toad medicine].
Erdmann E
Krankenpfl J; 2003; 41(4-6):110-1. PubMed ID: 12929321
[No Abstract] [Full Text] [Related]
3. [Legal boundaries of negative and positive lists].
Arndt M
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):630-2. PubMed ID: 9527457
[TBL] [Abstract][Full Text] [Related]
4. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
5. [The significance of the list of prescribable drugs (so-called positive list) for psychopharmacotherapy].
Fritze J; Schmauss M; Holsboer F;
Nervenarzt; 2003 Feb; 74(2):195-7. PubMed ID: 12683388
[No Abstract] [Full Text] [Related]
6. [Does red-green destroy phytotherapy?].
Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
[No Abstract] [Full Text] [Related]
7. [Off-label use of drugs--the legal framework].
Koyuncu A
Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
[No Abstract] [Full Text] [Related]
8. [Increased legal liability in off-label use].
Broglie M
Aktuelle Urol; 2006 Nov; 37(6):417-9. PubMed ID: 17153265
[No Abstract] [Full Text] [Related]
9. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
[No Abstract] [Full Text] [Related]
10. [Off-label prescriptions. Drug use outside of established guidelines and treatment standard].
Weissbach L; Boedefeld EA
Urologe A; 2003 Mar; 42(3):428-32. PubMed ID: 12723544
[No Abstract] [Full Text] [Related]
11. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
Wetterling T
Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
[TBL] [Abstract][Full Text] [Related]
12. [Positive list of drugs and osteoporosis].
Krankenpfl J; 2003; 41(4-6):113. PubMed ID: 12929324
[No Abstract] [Full Text] [Related]
13. [Expert evaluation of private drug prescriptions].
Kreck C; Saller R
Gesundheitswesen; 1995 May; 57(5):258-63. PubMed ID: 7620245
[TBL] [Abstract][Full Text] [Related]
14. [Solutions for off-label therapy].
Schmidt WA
Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
[TBL] [Abstract][Full Text] [Related]
15. [New cost saving legislation for drugs. National health insurance carriers do not want to believe Ulla Schmidt}].
MMW Fortschr Med; 2006 Feb; 148(5):45. PubMed ID: 16518939
[No Abstract] [Full Text] [Related]
16. [Limited prescribing freedom by federal cost regulation?].
Lasek R
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
[TBL] [Abstract][Full Text] [Related]
17. [Off-label use in oncology: an inexhaustible topic?!].
Weissbach L; Riese J
Urologe A; 2006 Nov; 45(11):1410, 1412-4. PubMed ID: 17043888
[TBL] [Abstract][Full Text] [Related]
18. [Family physicians resist high prescription risk].
Schmidt K
MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
[No Abstract] [Full Text] [Related]
19. [The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
Hellmich B; Gross WL
Z Rheumatol; 2003 Feb; 62(1):34-5. PubMed ID: 12624800
[No Abstract] [Full Text] [Related]
20. [Prescribing fictitiously approved drugs: regress threatens!].
Walbert H
MMW Fortschr Med; 2012 Apr; 154(6):10. PubMed ID: 22642016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
